The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Bruton Tyrosine Kinase (BTK) Inhibitor Market Research Report 2024

Global Bruton Tyrosine Kinase (BTK) Inhibitor Market Research Report 2024

Publishing Date : Jun, 2023

License Type :
 

Report Code : 1738356

No of Pages : 91

Ask Your Query

Synopsis
Bruton's tyrosine kinase (abbreviated Btk or BTK), also known as tyrosine-protein kinase BTK, is a tyrosine kinase that is encoded by the BTK gene in humans. BTK plays a crucial role in B cell development. Currently, BTK inhibitors are mainly applied in the treatments of hematological malignancies.

Global Bruton Tyrosine Kinase (BTK) Inhibitor market is projected to reach US$ 1817.5 million in 2029, increasing from US$ 886 million in 2022, with the CAGR of 10.9% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Bruton Tyrosine Kinase (BTK) Inhibitor market research.

Key manufacturers engaged in the Bruton Tyrosine Kinase (BTK) Inhibitor industry include Pfizer, Aptose Eiosciences, BeiGene, Hanmi Phamaceutical, Eli Lilly, Merck, Ono Phamaceutical, AbbVie and Zhejiang DTRM Biopharma, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % volume of Bruton Tyrosine Kinase (BTK) Inhibitor were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Bruton Tyrosine Kinase (BTK) Inhibitor market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Bruton Tyrosine Kinase (BTK) Inhibitor market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • Pfizer
  • Aptose Eiosciences
  • BeiGene
  • Hanmi Phamaceutical
  • Eli Lilly
  • Merck
  • Ono Phamaceutical
  • AbbVie
  • Zhejiang DTRM Biopharma
  • AstraZeneca
  • Biogen

Segment by Type

  • Tablet
  • Capsule

Segment by Application

  • Chronic Lymphocytic Leukemia (CLL)
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Waldenstrom Macroglobulinemia
  • Other Selective B Cell Malignancies
  • Chronic Graft-versus-host Disease
  • Others

Consumption by Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE)

The Bruton Tyrosine Kinase (BTK) Inhibitor report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source

Index

1 Bruton Tyrosine Kinase (BTK) Inhibitor Market Overview
1.1 Product Overview and Scope of Bruton Tyrosine Kinase (BTK) Inhibitor
1.2 Bruton Tyrosine Kinase (BTK) Inhibitor Segment by Type
1.2.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Market Value Comparison by Type (2023-2029)
1.2.2 Tablet
1.2.3 Capsule
1.3 Bruton Tyrosine Kinase (BTK) Inhibitor Segment by Application
1.3.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Market Value by Application: (2023-2029)
1.3.2 Chronic Lymphocytic Leukemia (CLL)
1.3.3 Follicular Lymphoma
1.3.4 Mantle Cell Lymphoma
1.3.5 Waldenstrom Macroglobulinemia
1.3.6 Other Selective B Cell Malignancies
1.3.7 Chronic Graft-versus-host Disease
1.3.8 Others
1.4 Global Bruton Tyrosine Kinase (BTK) Inhibitor Market Size Estimates and Forecasts
1.4.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Revenue 2018-2029
1.4.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sales 2018-2029
1.4.3 Global Bruton Tyrosine Kinase (BTK) Inhibitor Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Bruton Tyrosine Kinase (BTK) Inhibitor Market Competition by Manufacturers
2.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sales Market Share by Manufacturers (2018-2023)
2.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Bruton Tyrosine Kinase (BTK) Inhibitor Average Price by Manufacturers (2018-2023)
2.4 Global Bruton Tyrosine Kinase (BTK) Inhibitor Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Bruton Tyrosine Kinase (BTK) Inhibitor, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Bruton Tyrosine Kinase (BTK) Inhibitor, Product Type & Application
2.7 Bruton Tyrosine Kinase (BTK) Inhibitor Market Competitive Situation and Trends
2.7.1 Bruton Tyrosine Kinase (BTK) Inhibitor Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Bruton Tyrosine Kinase (BTK) Inhibitor Players Market Share by Revenue
2.7.3 Global Bruton Tyrosine Kinase (BTK) Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Bruton Tyrosine Kinase (BTK) Inhibitor Retrospective Market Scenario by Region
3.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Global Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Region: 2018-2029
3.2.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Region: 2018-2023
3.2.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Region: 2024-2029
3.3 Global Bruton Tyrosine Kinase (BTK) Inhibitor Global Bruton Tyrosine Kinase (BTK) Inhibitor Revenue by Region: 2018-2029
3.3.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Revenue by Region: 2018-2023
3.3.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Revenue by Region: 2024-2029
3.4 North America Bruton Tyrosine Kinase (BTK) Inhibitor Market Facts & Figures by Country
3.4.1 North America Bruton Tyrosine Kinase (BTK) Inhibitor Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Country (2018-2029)
3.4.3 North America Bruton Tyrosine Kinase (BTK) Inhibitor Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Bruton Tyrosine Kinase (BTK) Inhibitor Market Facts & Figures by Country
3.5.1 Europe Bruton Tyrosine Kinase (BTK) Inhibitor Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Country (2018-2029)
3.5.3 Europe Bruton Tyrosine Kinase (BTK) Inhibitor Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Bruton Tyrosine Kinase (BTK) Inhibitor Market Facts & Figures by Country
3.6.1 Asia Pacific Bruton Tyrosine Kinase (BTK) Inhibitor Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Country (2018-2029)
3.6.3 Asia Pacific Bruton Tyrosine Kinase (BTK) Inhibitor Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Bruton Tyrosine Kinase (BTK) Inhibitor Market Facts & Figures by Country
3.7.1 Latin America Bruton Tyrosine Kinase (BTK) Inhibitor Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Country (2018-2029)
3.7.3 Latin America Bruton Tyrosine Kinase (BTK) Inhibitor Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Bruton Tyrosine Kinase (BTK) Inhibitor Market Facts & Figures by Country
3.8.1 Middle East and Africa Bruton Tyrosine Kinase (BTK) Inhibitor Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Country (2018-2029)
3.8.3 Middle East and Africa Bruton Tyrosine Kinase (BTK) Inhibitor Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Type (2018-2029)
4.1.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Type (2018-2023)
4.1.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Type (2024-2029)
4.1.3 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sales Market Share by Type (2018-2029)
4.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Revenue by Type (2018-2029)
4.2.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Revenue by Type (2018-2023)
4.2.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Revenue by Type (2024-2029)
4.2.3 Global Bruton Tyrosine Kinase (BTK) Inhibitor Revenue Market Share by Type (2018-2029)
4.3 Global Bruton Tyrosine Kinase (BTK) Inhibitor Price by Type (2018-2029)
5 Segment by Application
5.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Application (2018-2029)
5.1.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Application (2018-2023)
5.1.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sales by Application (2024-2029)
5.1.3 Global Bruton Tyrosine Kinase (BTK) Inhibitor Sales Market Share by Application (2018-2029)
5.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Revenue by Application (2018-2029)
5.2.1 Global Bruton Tyrosine Kinase (BTK) Inhibitor Revenue by Application (2018-2023)
5.2.2 Global Bruton Tyrosine Kinase (BTK) Inhibitor Revenue by Application (2024-2029)
5.2.3 Global Bruton Tyrosine Kinase (BTK) Inhibitor Revenue Market Share by Application (2018-2029)
5.3 Global Bruton Tyrosine Kinase (BTK) Inhibitor Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Bruton Tyrosine Kinase (BTK) Inhibitor Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Pfizer Bruton Tyrosine Kinase (BTK) Inhibitor Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Aptose Eiosciences
6.2.1 Aptose Eiosciences Corporation Information
6.2.2 Aptose Eiosciences Description and Business Overview
6.2.3 Aptose Eiosciences Bruton Tyrosine Kinase (BTK) Inhibitor Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Aptose Eiosciences Bruton Tyrosine Kinase (BTK) Inhibitor Product Portfolio
6.2.5 Aptose Eiosciences Recent Developments/Updates
6.3 BeiGene
6.3.1 BeiGene Corporation Information
6.3.2 BeiGene Description and Business Overview
6.3.3 BeiGene Bruton Tyrosine Kinase (BTK) Inhibitor Sales, Revenue and Gross Margin (2018-2023)
6.3.4 BeiGene Bruton Tyrosine Kinase (BTK) Inhibitor Product Portfolio
6.3.5 BeiGene Recent Developments/Updates
6.4 Hanmi Phamaceutical
6.4.1 Hanmi Phamaceutical Corporation Information
6.4.2 Hanmi Phamaceutical Description and Business Overview
6.4.3 Hanmi Phamaceutical Bruton Tyrosine Kinase (BTK) Inhibitor Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Hanmi Phamaceutical Bruton Tyrosine Kinase (BTK) Inhibitor Product Portfolio
6.4.5 Hanmi Phamaceutical Recent Developments/Updates
6.5 Eli Lilly
6.5.1 Eli Lilly Corporation Information
6.5.2 Eli Lilly Description and Business Overview
6.5.3 Eli Lilly Bruton Tyrosine Kinase (BTK) Inhibitor Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Eli Lilly Bruton Tyrosine Kinase (BTK) Inhibitor Product Portfolio
6.5.5 Eli Lilly Recent Developments/Updates
6.6 Merck
6.6.1 Merck Corporation Information
6.6.2 Merck Description and Business Overview
6.6.3 Merck Bruton Tyrosine Kinase (BTK) Inhibitor Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Merck Bruton Tyrosine Kinase (BTK) Inhibitor Product Portfolio
6.6.5 Merck Recent Developments/Updates
6.7 Ono Phamaceutical
6.6.1 Ono Phamaceutical Corporation Information
6.6.2 Ono Phamaceutical Description and Business Overview
6.6.3 Ono Phamaceutical Bruton Tyrosine Kinase (BTK) Inhibitor Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Ono Phamaceutical Bruton Tyrosine Kinase (BTK) Inhibitor Product Portfolio
6.7.5 Ono Phamaceutical Recent Developments/Updates
6.8 AbbVie
6.8.1 AbbVie Corporation Information
6.8.2 AbbVie Description and Business Overview
6.8.3 AbbVie Bruton Tyrosine Kinase (BTK) Inhibitor Sales, Revenue and Gross Margin (2018-2023)
6.8.4 AbbVie Bruton Tyrosine Kinase (BTK) Inhibitor Product Portfolio
6.8.5 AbbVie Recent Developments/Updates
6.9 Zhejiang DTRM Biopharma
6.9.1 Zhejiang DTRM Biopharma Corporation Information
6.9.2 Zhejiang DTRM Biopharma Description and Business Overview
6.9.3 Zhejiang DTRM Biopharma Bruton Tyrosine Kinase (BTK) Inhibitor Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Zhejiang DTRM Biopharma Bruton Tyrosine Kinase (BTK) Inhibitor Product Portfolio
6.9.5 Zhejiang DTRM Biopharma Recent Developments/Updates
6.10 AstraZeneca
6.10.1 AstraZeneca Corporation Information
6.10.2 AstraZeneca Description and Business Overview
6.10.3 AstraZeneca Bruton Tyrosine Kinase (BTK) Inhibitor Sales, Revenue and Gross Margin (2018-2023)
6.10.4 AstraZeneca Bruton Tyrosine Kinase (BTK) Inhibitor Product Portfolio
6.10.5 AstraZeneca Recent Developments/Updates
6.11 Biogen
6.11.1 Biogen Corporation Information
6.11.2 Biogen Bruton Tyrosine Kinase (BTK) Inhibitor Description and Business Overview
6.11.3 Biogen Bruton Tyrosine Kinase (BTK) Inhibitor Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Biogen Bruton Tyrosine Kinase (BTK) Inhibitor Product Portfolio
6.11.5 Biogen Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Bruton Tyrosine Kinase (BTK) Inhibitor Industry Chain Analysis
7.2 Bruton Tyrosine Kinase (BTK) Inhibitor Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Bruton Tyrosine Kinase (BTK) Inhibitor Production Mode & Process
7.4 Bruton Tyrosine Kinase (BTK) Inhibitor Sales and Marketing
7.4.1 Bruton Tyrosine Kinase (BTK) Inhibitor Sales Channels
7.4.2 Bruton Tyrosine Kinase (BTK) Inhibitor Distributors
7.5 Bruton Tyrosine Kinase (BTK) Inhibitor Customers
8 Bruton Tyrosine Kinase (BTK) Inhibitor Market Dynamics
8.1 Bruton Tyrosine Kinase (BTK) Inhibitor Industry Trends
8.2 Bruton Tyrosine Kinase (BTK) Inhibitor Market Drivers
8.3 Bruton Tyrosine Kinase (BTK) Inhibitor Market Challenges
8.4 Bruton Tyrosine Kinase (BTK) Inhibitor Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock